Nishat Bharwani1, Marc E. Miquel2, Thomas Powles3, Redha Boubertakh2, Anju Sahdev1, Rodney H. Reznek1, Andrea G. Rockall1
1Radiology, Barts & the London NHS Trust, London, United Kingdom; 2Medical Physics, Barts & the London NHS Trust, London, United Kingdom; 3Medical Oncology, Barts & the London NHS Trust, London, United Kingdom
In recent years there has been a shift in the treatment options available for metastatic renal cell carcinoma (RCC). There is a clinical need for early identification of subsets of patients who will respond to these new targeted therapies. To our knowledge, our work with sequential diffusion weighted MRI (DW-MRI) is the first to demonstrate that dynamic changes occur with sunitinib therapy. Correlation of these changes with overall survival is required to establish their prognostic significance. This work may therefore lead to the first steps towards individualized therapy in metastatic RCC.